GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
2.4 EUR
0 (0%)
Taking everything into account, ALGEN scores 4 out of 10 in our fundamental rating. ALGEN was compared to 83 industry peers in the Biotechnology industry. ALGEN has an average financial health and profitability rating. While showing a medium growth rate, ALGEN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year ALGEN was profitable.
- ALGEN had a negative operating cash flow in the past year.
- In multiple years ALGEN reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
1.2 Ratios
- ALGEN has a Return On Assets of 3.31%. This is amongst the best in the industry. ALGEN outperforms 80.72% of its industry peers.
- The Return On Equity of ALGEN (7.00%) is better than 80.72% of its industry peers.
- With a decent Return On Invested Capital value of 3.17%, ALGEN is doing good in the industry, outperforming 74.70% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 12.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.31% | ||
| ROE | 7% | ||
| ROIC | 3.17% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of ALGEN (6.14%) is better than 80.72% of its industry peers.
- ALGEN has a Operating Margin of 5.97%. This is in the better half of the industry: ALGEN outperforms 75.90% of its industry peers.
- ALGEN has a better Gross Margin (94.91%) than 91.57% of its industry peers.
- In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.97% | ||
| PM (TTM) | 6.14% | ||
| GM | 94.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
- ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
- Compared to 5 years ago, ALGEN has more shares outstanding
- The debt/assets ratio for ALGEN has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.73, we must say that ALGEN is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.73, ALGEN is in the better half of the industry, outperforming 67.47% of the companies in the same industry.
- A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
- ALGEN has a Debt to Equity ratio (0.71) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.73 |
ROIC/WACC0.44
WACC7.19%
2.3 Liquidity
- ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.41, ALGEN is in line with its industry, outperforming 51.81% of the companies in the same industry.
- ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.21, ALGEN is in line with its industry, outperforming 51.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
- ALGEN shows a decrease in Revenue. In the last year, the revenue decreased by -2.21%.
- The Revenue has been growing by 18.46% on average over the past years. This is quite good.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
3.2 Future
- ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
- The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.00, the valuation of ALGEN can be described as correct.
- ALGEN's Price/Earnings ratio is rather cheap when compared to the industry. ALGEN is cheaper than 87.95% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.33, ALGEN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaper than 89.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.21 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
- ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALGEN (1/14/2026, 7:00:00 PM)
2.4
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap22.75M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (150.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16 | ||
| Fwd PE | N/A | ||
| P/S | 1.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.24 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | 8.21 |
EPS(TTM)0.15
EY6.25%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS2.21
BVpS1.94
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.31% | ||
| ROE | 7% | ||
| ROCE | 3.94% | ||
| ROIC | 3.17% | ||
| ROICexc | 3.17% | ||
| ROICexgc | 3.91% | ||
| OM | 5.97% | ||
| PM (TTM) | 6.14% | ||
| GM | 94.91% | ||
| FCFM | N/A |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.88 | ||
| Cap/Depr | 297.91% | ||
| Cap/Sales | 46.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 1.73 |
F-Score3
WACC7.19%
ROIC/WACC0.44
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.
What is the valuation status of GENOWAY SA (ALGEN.PA) stock?
ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.
What is the profitability of ALGEN stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for ALGEN stock?
The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16 and the Price/Book (PB) ratio is 1.24.
What is the financial health of GENOWAY SA (ALGEN.PA) stock?
The financial health rating of GENOWAY SA (ALGEN.PA) is 4 / 10.